ActivX Biosciences Announces Agreement with Gilead Sciences for Protein Activity Profiling.Business Editors/Health/Medical Writers BIOWIRE2K LA JOLLA La Jolla (lə hoi`yə), on the Pacific Ocean, S Calif., an uninc. district within the confines of San Diego; founded 1869. The beautiful ocean beaches, in particular La Jolla shores and Black's Beach, and sea-washed caves attract visitors and , Calif.--(BUSINESS WIRE)--April 6, 2004 ActivX Biosciences, Inc., a privately held biotechnology company applying novel chemical technologies and high-throughput protein analysis to drug discovery and development, announced today it has entered into an agreement with Gilead Sciences Gilead Sciences NASDAQ: GILD is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. of Foster City, California
Under the agreement, ActivX will utilize its proprietary technology to analyze specific proteins to provide a greater understanding of the biological activity of Gilead's compounds. Financial terms of the agreement were not announced. "ActivX's proprietary technology to rapidly and definitively characterize the activities of important protein families continues to generate excitement in the pharmaceutical industry. Our new agreement with Gilead provides ActivX with a unique opportunity to demonstrate the value of our technology to a leading biopharmaceutical company," said John W. Kozarich, PhD., President and Chief Research & Development Officer of ActivX. With this partnership, ActivX continues to validate its technology by further building a strong portfolio of corporate partnerships, which currently include Kyorin Pharmaceutical Co. and Pfizer. ActivX Biosciences, Inc., based in La Jolla, California, is a privately held drug discovery and development company. ActivX's proprietary chemical technologies and high-throughput protein analysis capabilities are being applied to advancing both its own internal drug pipeline as well as the development efforts of its pharmaceutical and biotechnology partners. By focusing specifically on functional proteins, ActivX addresses disease mechanisms directly; taking an approach that differs from that of traditional drug discovery and development methods. ActivX technology address critical challenges in drug discovery, such as selectivity selectivity /se·lec·tiv·i·ty/ (se-lek-tiv´i-te) in pharmacology, the degree to which a dose of a drug produces the desired effect in relation to adverse effects. selectivity 1. profiling of drug candidates across entire protein families in biological samples to guide their medicinal chemistry Medicinal or pharmaceutical chemistry is a scientific discipline at the intersection of chemistry and pharmacology involved with designing, synthesizing and developing pharmaceutical drugs. optimization optimization Field of applied mathematics whose principles and methods are used to solve quantitative problems in disciplines including physics, biology, engineering, and economics. ; identification of novel drug targets and biomarkers; and characterization A rather long and fancy word for analyzing a system or process and measuring its "characteristics." For example, a Web characterization would yield the number of current sites on the Web, types of sites, annual growth, etc. of off-target activities of candidate and established drugs to understand the basis for their efficacy and toxicity toxicity /tox·ic·i·ty/ (tok-sis´i-te) the quality of being poisonous, especially the degree of virulence of a toxic microbe or of a poison. . For more information on ActivX Biosciences, please visit the company's Website at http://www.activx.com |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion